Peptide-specific CD8+ T-cell evolution in vivo: Response to peptide vaccination with Melan-A/MART-1

International Journal of Cancer

Volumn 98, Issue 3, 2002, Pages 376-388

  Jäger, Elke ^a   Höhn, Hauni ^b   Necker, Artje ^c   Förster, Reinhold ^d   Karbach, Julia ^a   Freitag, Kirsten ^b   Neukirch, Claudia ^b   Castelli, Chiara ^e   Salter, Russell D ^f   Knuth, Alaxander ^a   Maeurer, Markus J ^b,g  

^a KRANKENHAUS NORDWEST   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c Immunomics Operations   (France)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g Inst of Med Microbiol and Hygiene   (Germany)

Author keywords

Immunotherapy; Melanoma; T cells; TCR; Vaccination

Indexed keywords

CD45 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A2 ANTIGEN; INTERLEUKIN 2; MELAN A; MELAN A DERIVATIVE; MELANOMA VACCINE; RECOMBINANT HLA A2 ANTIGEN; T LYMPHOCYTE RECEPTOR; TETRAMER; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DRUG EFFICACY; EPITOPE MAPPING; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; LYMPHOCYTE SUBPOPULATION; MELANOMA; MEMORY CELL; MOLECULAR BIOLOGY; MOLECULAR EVOLUTION; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; VACCINATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ATP-BINDING CASSETTE TRANSPORTERS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; COMPLEMENTARITY DETERMINING REGIONS; FLOW CYTOMETRY; HLA-A2 ANTIGEN; HUMANS; MELANOMA; NEOPLASM PROTEINS; OLIGOPEPTIDES; PHENOTYPE; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL; SKIN NEOPLASMS; TUMOR CELLS, CULTURED; VACCINATION; VACCINES, SUBUNIT;

EID: 0037139370     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10165     Document Type: Article

References (52)

1. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo
2. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
3. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers
4. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA- A1
5. The composition of a primary T cell response is largely determined by the timing of recruitment of individual T cell clones
6. Single-cell PCR analysis of TCR repertoires selected by antigen in vivo: A high magnitude CD8 response is comprised of very few clones
7. Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses
8. TCR beta-chain variable region-driven selection and massive expansion of HLA-class I-restricted antitumor CTL lines from HLA-A*0201+ melanoma patients
9. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers
10. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
11. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals
12. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
13. Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients
14. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
15. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
16. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes
17. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
18. Skewed maturation of memory HIV-specific CD8 T lymphocytes
19. Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class 1 and peptide with reduced CD8 binding
20. Improved detection of melanoma antigen-specific T cells expressing low or high levels of CD8 by HLA-A2 tetramers presenting a Melan-A/MART-1 peptide analogue
21. Critical role for CD8 in binding of MHC tetramers to TCR: CD8 antibodies block specific binding of human tumor- specific mhc-peptide tetramers to TCR
22. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma- associated peptides
23. An experimentally validated panel of subfamily-specific oligonucleotide primers (V alpha 1-w29/V beta 1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction
24. Oligoclonality of tumor-infiltrating lymphocytes from human melanomas
25. Monoclonal TCR mRNA transcripts are preferentially detected in the TCR variable alpha chain in CD8(+) T-lymphocytes: Implications for immunomonitoring
26. T-cell repertoire diversity and clonal expansions in normal and clinical samples
27. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy
28. Phenotypic and functional separation of memory and effector human CD8+ T cells
29. Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-I/Melan-A
30. Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues
31. Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35)
32. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35)
33. CTL response to Mycobacterium tuberculosis: Identification of an immunogenic epitope in the 19-kDa lipoprotein
34. Antigen-processing machinery breakdown and tumor growth
35. High frequency of T cell clonal expansions in primary human melanoma. Involvement of a dominant clonotype in autologous tumor recognition
36. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo
37. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen- experienced tumor-specific cytolytic T lymphocytes
38. Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype
39. Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors
40. Changes in thymic function with age and during the treatment of HIV infection
41. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo
42. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex
43. CD8 T cells specific for human immunodeficiency virus, Epstein-Bart virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection
44. Lymphocyte subsets in the blood: A diagnostic window on the lymphoid system?
45. Visualizing the generation of memory CD4 T cells in the whole body
46. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination
47. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response
48. The chemokine receptor switch paradigm and dendritic cell migration: Its significance in tumor tissues
49. Antigenic oscillations and shifting immunodominance in HIV-1 infections
50. Qualitative and quantitative differences in T cell receptor binding of agonist and antagonist ligands
51. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions
52. Individual variations in the murine T cell response to a specific peptide reflect variability in naive repertoires